Abstract:The central role of platelets in thrombosis is well characterized. Recently, evidence has emerged that platelets also play crucial roles in inflammation and cancer. Therefore, reliable and sensitive imaging of activated platelets holds promise to improve diagnosis in numerous diseases and addresses a significant clinical need. 1 Here, we describe an innovative method for imaging activated platelets using advanced fluorine‐19 ( 19 F) magnetic resonance imaging (MRI). MRI provides high‐resolution imaging, even in deep tissues, without harmful ionizing radiation. Visualization of thrombi, inflammation, early cancer, and metastases is difficult since these structures are often not well differentiated against surrounding tissues. MRI contrast based on gadolinium or iron oxide has been employed to improve tissue differentiation. However, these contrast agents are imaged using conventional hydrogen ( 1 H)‐based MRI and are sometimes difficult to differentiate from anatomical structure. An alternative, 19 F‐based MRI holds promise for greater specificity. 19 F is essentially absent from biological tissue, allowing for background‐free localization. The merge of 1 H and 19 F data sets allows for exact anatomical localization and molecular characterization. Furthermore, the linear relationship between fluorine concentration and signal intensity permits direct quantification of contrast agent accumulation. 19 F MRI contrast agents are typically generated using perfluorocarbons, which are chemically and biologically inert, rendering them safe for in vivo use. 2 Perfluorocarbons are emulsified with phospholipids to form stable, biocompatible, and intravenously administrable nanoemulsions (PFCs). Non‐conjugated PFCs are phagocytosed by monocytes/macrophages, a method utilized for imaging of inflammation in mouse models of myocardial and cerebral ischemia, myocarditis, and pneumonia. 1 Direct targeting of PFCs, independent of phagocytosis, using small antiplasmin peptide–conjugated PFCs were successfully employed to detect the early phase of venous thrombosis via 19 F MRI. 3 To achieve selective targeting of activated platelets, we chose to target the activated conformation of integrin glycoprotein IIb/IIIa (GPIIb/IIIa; α IIb β 3 , CD41/CD61). GPIIb/IIIa is highly specific for platelets and is the most abundantly expressed receptor on the platelet surface (≈60 000 receptors per platelet). Upon platelet activation, GPIIb/IIIa undergoes a conformational change with the selective exposure of specific epitopes. 4 We generated a unique human single‐chain antibody (scFv), that binds specifically to the activated conformation of GPIIb/IIIa (scFv Targ ), and exhibits the same binding profile on human and mouse platelets, providing a distinct advantage for cross‐species testing. 4 , 5 The scFv Targ does not bind to nonactivated circulating platelets or to other proteins or cells in the blood. 4 This scFv Targ has been successfully used for molecular imaging of diseases across a range of imaging technologies, including ultrasound, positron emission tomography, fluorescence emission computed tomography, and conventional MRI. 1 , 4 , 5 We have now established an antibody‐targeted, 19 F‐based MRI approach that enables selective imaging of activated platelets, with a large scope of potential applications, such as in the diagnosis of atherothrombotic, inflammatory, and malignant diseases. For imaging of activated platelets by 19 F MRI, we generated dual‐modality PFCs, which were functionalized with a biotin‐lipid for conjugation with the scFv and a fluorescence dye. PFCs containing 0.01 mol% biotin‐DHPE were coated with neutravidin and washed by centrifugation. Biotinylated scFv Targ was then coupled to the neutravidin moiety of the perfluorocarbons ( Targ PFCs). As a control, we conjugated a non‐targeted, nonbinding scFv Non‐targ to the PFCs ( Non‐targ PFCs). Targeting properties of these PFCs were confirmed using a flow‐chamber adhesion assay using human blood 4 , <a class="t -Abstract Truncated-

Imaging of thromboembolism with ~(99)Tc~m-SZ21F(ab)_2,a humanized anti-platelet glycoprotein IIIa monoclonai antibody F(ab)_2 fragment

Imaging Thromboembolism with 99mtc Labelled Chimeric Monoclonal Anti-Platelet Glycoprotein Iiia Antibody Fragment Chsz21f(ab)2: Evaluation in Beagle Canines

Detection of Thromboembolism with 99Mtc-Labeled F(ab)2 Fragment of Anti-glycoprotein IIIa Chimeric Monoclonal Antibody in Beagle Canines

Imaging of thromboembolism with 99Tcm-SZ21F ( ab ) 2, a humanized anti-platelet glycoprotein III a monoclonal antibody F(ab) 2 fragment

Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody Fragment.

Detection of Experimental Pulmonary Thrombosis and Deep Venous Thrombosis by 99Tcm-Dmp444

Synthesis of Labelled Small Peptide Complexes for Imaging Agents with Technetium-99M and Biodistribution in Mice.

64Cu-Labeled Divalent Cystine Knot Peptide for Imaging Carotid Atherosclerotic Plaques.

99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression

<sup>99m</sup>Tc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin α<sub>v</sub>β<sub>3</sub>Expression

Imaging of 99Tcm-Labeled New Cyclic RGDfK Dimer in Nude Mice Bearing U87MG Human Glioma Xenografts

[Noninvasive Detection of Experimental Vulnerable Atherosclerotic Plaques with 99tc M Labeled C2A Domain of Synaptotagmin I].

Evaluation of a 99Mtc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin Αvβ3-Positive Breast Cancer

18F Site-Specific Labelling of a Single-Chain Antibody against Activated Platelets for the Detection of Acute Thrombosis in Positron Emission Tomography

99Mtco(mag2-3G3-dimer): a New Integrin Αvβ3-Targeted SPECT Radiotracer with High Tumor Uptake and Favorable Pharmacokinetics

Bio-distribution study of Tc-99m HMPAO labeled platelet in healthy volunteer

Fluorine-19 Magnetic Resonance Imaging of Activated Platelets.

A potential thrombus diagnosis reagent based on P-selectin monoclonal antibody SZ-51 light chain.

99m TcO(MAG 2 -3G 3 -dimer): a new integrin α v β 3 -targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics

99Mtc-3Prgd2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study

99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression.